Ritalin LA "approvable" letter
Executive Summary
Novartis and Celgene expect to launch once-daily formulation of methylphenidate (Ritalin LA) during the fourth quarter after responding to Oct. 2 "approvable" letter from FDA
You may also be interested in...
Novartis Focalin Price Similar To Ritalin; ADHD Drug Clears FDA Nov. 13
Novartis' Focalin will be priced similarly to its parent compound Ritalin, the company said following the Nov. 13 approval of the attention deficit hyperactivity disorder drug
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011